HER2-directed therapy in CCA has been evaluated in MyPathway, which was a non-randomized, multicenter, open-label, phase 2a basket study that enrolled 39 patients with advanced, previously treated biliary tract malignancies with HER2 amplification and/or overexpression [39]. This evidence concerns the gene ERBB2 and medical procedure.